Sunday, March 25, 2018 9:23:09 AM
Apparently some here don’t know what a “letter of intent” means.
Here’s a simple definition: a one-sided, not yet negotiated proposal of an offer from one company to another OR a statement that only describes a future proposal of an offer
The fact that they threw the word “binding” in order to mislead novice investors is laughable. Anyone with even the slightest knowledge of business knows there’s no such thing as a “binding LOI”
A proposal that has yet to be accepted or executed is far from a material event. And seriously, cancellation of a reverse split? All the more reason to believe rhat the company is SELLING SHARES. That’s why they needed the reverse split in the first place BECAUSE THE COMPANY HAS AN EXTENSIVE HISTORY OF USING TOXIC DILUTION TO PAY THEIR RECURRING BILLS. Come on people, use your heads.
The truth comes out this week and we’ll all find out if SHMN is a scam like the other 99% of delinquent pink companies.
Here’s a simple definition: a one-sided, not yet negotiated proposal of an offer from one company to another OR a statement that only describes a future proposal of an offer
The fact that they threw the word “binding” in order to mislead novice investors is laughable. Anyone with even the slightest knowledge of business knows there’s no such thing as a “binding LOI”
A proposal that has yet to be accepted or executed is far from a material event. And seriously, cancellation of a reverse split? All the more reason to believe rhat the company is SELLING SHARES. That’s why they needed the reverse split in the first place BECAUSE THE COMPANY HAS AN EXTENSIVE HISTORY OF USING TOXIC DILUTION TO PAY THEIR RECURRING BILLS. Come on people, use your heads.
The truth comes out this week and we’ll all find out if SHMN is a scam like the other 99% of delinquent pink companies.
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
